Samsung Biologics proposed an all-cash tender offer of about $1.8 billion to acquire PolyPeptide Group, positioning the acquisition as a modality expansion into peptide therapeutics. The deal would integrate PolyPeptide’s peptide API development-to-commercial capabilities with Samsung’s manufacturing scale, with emphasis on peptide demand driven by obesity and diabetes treatments. The acquisition is framed as end-to-end capability expansion rather than capacity-only growth, citing PolyPeptide’s integrated global footprint across Sweden, Belgium, France, the U.S., and India. Samsung also highlighted a late-stage portfolio of peptide projects as immediate commercial opportunity. For the biomanufacturing ecosystem, the transaction signals accelerating CDMO competition across modalities beyond antibodies and ADCs, with peptide expertise increasingly treated as strategic capacity.